Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer

• Published in: Cancer science Vol. 115; no. 5; pp. 1656 - 1664
• Main Authors: Ishida, Masaki, Iwasaku, Masahiro, Doi, Toshifumi, Ishikawa, Takeshi, Tachibana, Yusuke, Sawada, Ryo, Ogura, Yuri, Kawachi, Hayato, Katayama, Yuki, Nishioka, Naoya, Morimoto, Kenji, Tokuda, Shinsaku, Yamada, Tadaaki, Takayama, Koichi
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.05.2024
• Subjects: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase - genetics; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; ErbB Receptors - genetics; Female; Gene Expression Profiling - methods; Genomics - methods; High-Throughput Nucleotide Sequencing - methods; Humans; Japan; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Mutation; Oncogenes - genetics; Original; ORIGINAL ARTICLES; Protein-Tyrosine Kinases - genetics; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins p21(ras) - genetics; Receptor Protein-Tyrosine Kinases - genetics; Retrospective Studies; Japan; driver oncogenes; comprehensive genomic profiling; precision medicine; Center for Cancer Genomics and Advanced Therapeutics; non‐small cell lung cancer
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/cas.16130

Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patients with advanced solid tumors who had completed or were expected to complete standard chemotherapy. These assays are expected to comprehensively detect the driver oncogenes, especially for patients with non-small cell lung cancer (NSCLC). However, there are no reports of nationwide research on the detection of driver oncogenes in patients with advanced NSCLC who undergo CGP assays, especially in those with undetected driver oncogenes at diagnosis. In this study, we investigated the proportion of driver oncogenes detected in patients with advanced NSCLC with undetectable driver oncogenes at initial diagnosis and in all patients with advanced NSCLC who underwent CGP assays. We retrospectively analyzed data from 986 patients with advanced NSCLC who underwent CGP assays between August 2019 and March 2022, using the Center for Cancer Genomics and Advanced Therapeutics database. The proportion of driver oncogenes newly detected in patients with NSCLC who tested negative for driver oncogenes at diagnosis and in all patients with NSCLC were investigated. Driver oncogenes were detected in 451 patients (45.7%). EGFR was the most common (16.5%), followed by KRAS (14.5%). Among the 330 patients with undetected EGFR, ALK, ROS1, and BRAF V600E mutations at diagnosis, 81 patients (24.5%) had newly identified driver oncogenes. CGP assays could be useful to identify driver oncogenes in patients with advanced NSCLC, including those initially undetected, facilitating personalized treatment.